|
Stryker Biotech and Its Top Management Indicted for Illegal Promotion of Medical Devices Used in Invasive Surgeries
BOSTON, MA—Stryker Biotech, LLC, a corporation based in Hopkinton,
Massachusetts, and its former president, Mark Philip of Lexington, Massachusetts, and its
current sales managers, William Heppner of Illinios, David Ard of California, and Jeff Whitaker
of North Carolina, were charged today in federal court with participating in a fraudulent
marketing scheme of medical devices used during invasive spinal and long bone surgeries.
Stryker Biotech and Mark Philip were also charged with making false statements to the United
States Food and Drug Administration (“FDA”).
Acting United States Attorney Michael K. Loucks; Mark Dragonetti, Resident Agent in
Charge of the Food & Drug Administration - Office of Criminal Investigations; Susan J.
Waddell, Special Agent in Charge of Health and Human Services, Office of the Inspector
General - Office of Investigations; and Warren T. Bamford, Special Agent in Charge of the
Federal Bureau of Investigation - Boston Field Division, announced today that STRYKER
BIOTECH, LLC, MARK PHILIP, WILLIAM HEPPNER, DAVID ARD and JEFF
WHITAKER were charged in an Indictment with five counts of wire fraud and one count of
conspiracy. STRYKER BIOTECH, DAVID ARD and JEFF WHITAKER were also charged
with misbranding. In addition, STRYKER BIOTECH and MARK PHILIP were charged with
making false statements to the FDA.
The Indictment alleges that all of the defendants participated in an illegal marketing
scheme to promote medical devices used during invasive surgeries, and in doing so having
defrauded medical professionals and the FDA. In particular, the defendants are alleged to have
promoted devices known as OP-1 Implant and OP-1 Putty. These devices were used to stimulate
bone growth in long bones and the spine. These devices were approved by the FDA only
pursuant to a highly restrictive Humanitarian Device Exemption (“HDE”). One of the
restrictions was that the device could only treat a condition that affected fewer than 4,000
patients in the United States, and could not be sold for a profit. The Indictment charges that the
defendants promoted the use of these devices in a manner that was different from its FDA
approved use; namely they promoted a combination of the devices with a bone void filler, called
Calstrux, and in furtherance of that promotion provided “recipes” to surgeons, medical
technicians and others as to how to mix the OP-1 products with Calstrux. It is alleged that some
of these untested “recipes” called for medical personnel to mold the combined product into
“cigars,” “tootsie rolls” or “vienna sausages.” The Indictment charges that the defendants knew
that such a combination had never been studied in a clinical trial and had never been presented to
or approved by the FDA. It is alleged that the reason the defendants promoted the OP-1 products
in a mixture with Calstrux was because without a mixing agent, the OP-1 products were at a
competitive disadvantage with other legal products. The Indictment also alleges that serious
medical problems arose in a number of patients from this untested mix of products.
The Indictment also charges that defendants STRYKER BIOTECH, LLC and MARK
PHILIP made false statements to the FDA about the number of patients that STRYKER
BIOTECH was treating on an annual basis with OP-1 Putty.
If convicted of the wire fraud, conspiracy, misbranding or false statements charges,
STRYKER BIOTECH faces fines of the greater of $500,000 or twice the gross gain or loss
from the offense, on each count.
If convicted on the wire fraud charges, MARK PHILIP, WILLIAM HEPPNER,
DAVID ARD and JEFF WHITAKER each face up to 20 years imprisonment, to be followed
by 3 years of supervised release and a fine of the greater of $250,000 or twice the gross gain or
loss from the offense, on each count. If convicted on the conspiracy charges, MARK PHILIP,
WILLIAM HEPPNER, DAVID ARD and JEFF WHITAKER each face up to 5 years
imprisonment, to be followed by 3 years of supervised release and fine of the greater of
$250,000 or twice the gross gain or loss from the offense, on each count.
If convicted on the misbranding charges, DAVID ARD and JEFF WHITAKER each
face up to 3 years imprisonment, to be followed by 1 year of supervised release and fine of the
greater of $250,000 or twice the gross gain or loss from the offense on each charge. If convicted
on the false statement charge, MARK PHILIP faces up to 5 years imprisonment, to be followed
by 3 years supervised release and fine of the greater of $250,000 or twice the gross gain or loss
from the offense.
The case was investigated by the Food & Drug Administration - Office of Criminal
Investigations, the Department of Health and Human Services - Office of Inspector General and
the Federal Bureau of Investigation. It is being prosecuted by Assistant U.S. Attorney Jeremy
Sternberg of Loucks’ Health Care Fraud Unit.
The details contained in the Indictment are allegations. The defendants are presumed to
be innocent unless and until proven guilty beyond a reasonable doubt in a court of law.
Press Releases | Boston Home
|
